{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:50:59Z","timestamp":1793742659031,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.esmoop.2023.101613","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T23:55:00Z","timestamp":1690070100000},"page":"101613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-6114","authenticated-orcid":false,"given":"L.R.","family":"Soares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0627-1023","authenticated-orcid":false,"given":"M.","family":"Vilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9137-9997","authenticated-orcid":false,"given":"V.D.L.","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Deus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-8598","authenticated-orcid":false,"given":"R.","family":"Freitas-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.esmoop.2023.101613_bib1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"DESTINY-Breast01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.101613_bib2","doi-asserted-by":"crossref","unstructured":"Krop I, Park YH, Kim SB, et\u00a0al. GS2-01 Trastuzumab deruxtecan vs physician\u2019s choice in patients with HER2+ unresectable and\/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02 [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium. December 6-10, 2022; San Antonio, TX. Philadelphia, PA: AACR; Cancer Res. 2023;83(suppl 5):Abstract nr GS2-01.","DOI":"10.1158\/1538-7445.SABCS22-GS2-01"},{"issue":"12","key":"10.1016\/j.esmoop.2023.101613_bib3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"DESTINY-Breast03 Trial Investigators. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10371","key":"10.1016\/j.esmoop.2023.101613_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101613_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"DESTINY-Breast04 Trial Investigators. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.101613_bib6","unstructured":"Trastuzumab deruxtecan clinical trials. ClinicalTrials.gov [cited 2023 Feb 22]. Available at https:\/\/clinicaltrials.gov\/search?term=trastuzumab%20deruxtecan&aggFilters=status. Accessed July 15, 2023."},{"key":"10.1016\/j.esmoop.2023.101613_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101613_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.esmoop.2023.101613_bib9","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101613_bib10","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101613_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101613_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cpt.2757","article-title":"Effect of trastuzumab deruxtecan on QT\/QTc interval and pharmacokinetics in HER2-positive or HER2-low metastatic\/unresectable breast cancer","volume":"113","author":"Shimomura","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.esmoop.2023.101613_bib13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(13)70502-3","volume":"14","author":"Buzdar","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101613_bib14","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019"},{"key":"10.1016\/j.esmoop.2023.101613_bib15","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.esmoop.2023.101613_bib17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14712598.2021.1890710","article-title":"Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond","volume":"21","author":"Perez","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101613_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.esmoop.2023.101613_bib19","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.esmoop.2023.101613_bib20","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.esmoop.2023.101613_bib21","doi-asserted-by":"crossref","unstructured":"Di\u00e9ras V, Deluche E, Lusque A, et\u00a0al. Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium. December 7-10, 2021; San Antonio, TX. Philadelphia, PA: AACR; Cancer Res. 2022;82(suppl 4):Abstract nr PD8-02.","DOI":"10.1158\/1538-7445.SABCS21-PD8-02"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101613_bib22","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101613_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.esmoop.2023.101613_bib24","doi-asserted-by":"crossref","unstructured":"Hamilton E, Jhaveri K, Loi S, et\u00a0al. Dose-expansion study of trastuzumab deruxtecan as monotherapy or combined with pertuzumab in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer in DESTINY-Breast07 (DB-07) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium. December 6-10, 2022; San Antonio, TX. Philadelphia, PA: AACR; Cancer Res. 2023;83(suppl 5):Abstract nr PD18-11.","DOI":"10.1158\/1538-7445.SABCS22-PD18-11"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2023.101613_bib25","article-title":"236P Trastuzumab deruxtecan in Italian real-world experience: updated analysis from DE-REAL study","volume":"8","author":"Botticelli","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.101613_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.breast.2022.01.002","article-title":"Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer","volume":"61","author":"Nakajima","year":"2022","journal-title":"Breast"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2023.101613_bib27","article-title":"237P Real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): the TREX-Old retrospective registry","volume":"8","author":"Buono","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.101613_bib28","doi-asserted-by":"crossref","unstructured":"Yamanaka T, Niikura N, Nomura H, et\u00a0al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and\/or leptomeningeal metastases: a multicenter retrospective study (ROSET-BM study) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium. December 6-10, 2022; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res. 2023;83(suppl 5):Abstract nr PD7-01.","DOI":"10.1158\/1538-7445.SABCS22-PD7-01"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101613_bib29","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101613_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4048\/jbc.2022.25.e1","article-title":"CT findings from interstitial lung diseases in patients with metastatic breast cancer treated with fam-trastuzumab deruxtecan: a single institutional experience","volume":"25","author":"Jang","year":"2022","journal-title":"J\u00a0Breast Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101613_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2023.101613_bib32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"},{"issue":"12","key":"10.1016\/j.esmoop.2023.101613_bib33","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101613_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.esmoop.2023.101613_bib35","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial\u00a0pneumonitis related to trastuzumab deruxtecan, a human\u00a0epidermal growth factor receptor 2-targeting Ab-drug\u00a0conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"issue":"16","key":"10.1016\/j.esmoop.2023.101613_bib37","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-20-4557","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:30:23Z","timestamp":1761856223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923008487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2059702923008487"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101613","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101613"}}